News
API and Eli Lilly launch nationwide CME programme to strengthen obesity care among indian physicians
The Obesity Gurukul initiative will train over 20,000 healthcare professionals across India through a hybrid education model ...
The initiative will provide practical insights into understanding of obesity pathophysiology and its management.
"Obesity is a complex, chronic condition that requires more than just treatment--it demands continuous medical education, empathy, and coordinated action across the healthcare ecosystem," said Dr.
Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program
Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...
Referrals to an obesity clinic almost doubled after a novel educational intervention addressed negative attitudes and suboptimal practice patterns.
A collection of top researchers have made the case for a new way to understand and diagnose obesity beyond using BMI as a measure.
Obesity-Focused Growth Trajectories of LLY & AMGN Eli Lilly and Company LLY has advanced its leadership in the obesity treatment space with key developments in both injectables and oral therapies.
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio.
Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major competitor in China.
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results